In order to identify compounds active for this tumor subtype, we performed a large-scale high-throughput screening (HTS) and compared to the sensitivity of patient two-derived cell line HPG-RBG1 with Y79 (commercial cell line with RB1−/− and MYCN amplification) and HPG-RBT-12L (derived from an untreated human intraocular tumor with no MYCN amplification [16]). This evidence concerns the gene MYCN and neoplasm.